{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:10:38Z","timestamp":1787674238184,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR P2022RLH39"],"award-info":[{"award-number":["PNRR P2022RLH39"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P2022RZ8WM"],"award-info":[{"award-number":["P2022RZ8WM"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009876","name":"Regione Basilicata","doi-asserted-by":"publisher","award":["G46C2000000009"],"award-info":[{"award-number":["G46C2000000009"]}],"id":[{"id":"10.13039\/501100009876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007706","name":"Ministero dello Sviluppo Economico","doi-asserted-by":"publisher","award":["F\/180022\/04\/X43"],"award-info":[{"award-number":["F\/180022\/04\/X43"]}],"id":[{"id":"10.13039\/501100007706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","award":["DBA.AD005.225"],"award-info":[{"award-number":["DBA.AD005.225"]}],"id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant mesothelioma (MM) is a rare and aggressive form of cancer that affects the mesothelial surfaces, associated with exposure to asbestos fibres. To date, no cure is available for MM and therapeutically approved treatments are based on the use of platinum compounds often used in combination with other drugs. We have previously analysed the efficacy of a cisplatin\/piroxicam (CDDP\/P) combined treatment showing that this treatment was able to reduce in vivo tumor growth. Several studies reported that platinum-drug sensitivity in cancer is connected to modulation of the expression of non-coding RNAs. In this study we analysed if the CDDP\/P treatment was able to modulate miRNAs expression in MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>miRNA sequencing performed on MSTO-211\u00a0H cells treated with CDDP with CDDP\/P led us to identify miRNA-503 - downregulated by CDDP\/P - as a novel miRNA that acts as an oncomiR in MM. The effect of miRNA-503 inhibition was evaluated in vitro in mesothelioma cells analysing apoptosis induction and reduction of cancer properties. Inhibition of miR-503 expression in vivo, was analysed in ectopic mouse model of MM by using LNP encapsulating anti-mir-503 and miR-503 expression was evaluated in human MM samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vitro and in vivo analysis confirmed miR-503 acts as oncogene in MM since its inhibition was able to reduce cell cancer properties and tumor growth in ectopic mouse model of MM. Its expression was found upregulated in human MM patients compared to normal pleura. Bioinformatic analysis indicated BTG1, CCNG1, EDG1, and TIMP2 as putative target genes of miRNA-503. These genes showed an opposite expression compared to miR-503 levels both in cells and in MM samples. Finally, microarray analysis indicated that miR-503 inhibition affected the expression of the well-known MM biomarkers: CXCL8, SERPINE1 and Osteopontin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study is the first reporting an oncomiR role for miR-503 in MM and suggests that its inactivation could have a clinical value in MM patients. This study reveals that miRNA-503 acts as an oncomiR in MM suggesting that its inhibition, through LNP delivery, has the potential to be considered as a novel therapeutic strategy in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03283-0","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:29:31Z","timestamp":1740176971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["miRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma"],"prefix":"10.1186","volume":"44","author":[{"given":"Miriam","family":"Piccioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Meo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Campani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Arigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Tanori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Cuciniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tomasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Goteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico P.","family":"Spugnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele A.","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Crispi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"11","key":"3283_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2471\/BLT.13.132118","volume":"92","author":"T Kameda","year":"2014","unstructured":"Kameda T, et al. Asbestos: use, bans and disease burden in Europe. Bull World Health Organ. 2014;92(11):790\u20137.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"3283_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.lungcan.2005.03.002","volume":"49","author":"L Kazan-Allen","year":"2005","unstructured":"Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer. 2005;49(1):S3\u20138.","journal-title":"Lung Cancer"},{"issue":"2","key":"3283_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jtcvs.2015.09.086","volume":"151","author":"T Treasure","year":"2016","unstructured":"Treasure T. What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice. J Thorac Cardiovasc Surg. 2016;151(2):307\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3283_CR4","doi-asserted-by":"crossref","unstructured":"Cuciniello R, Filosa S, Crispi S. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics. J Exp Clin Cancer Res. 2021;40(1):383","DOI":"10.1186\/s13046-021-02193-1"},{"issue":"7\u20138","key":"3283_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41417-018-0025-2","volume":"25","author":"M Panagal","year":"2018","unstructured":"Panagal M, et al. MicroRNA21 and the various types of myeloid leukemia. Cancer Gene Ther. 2018;25(7\u20138):161\u20136.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"3283_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11684-013-0252-8","volume":"7","author":"R Zhang","year":"2013","unstructured":"Zhang R, et al. The role of microRNAs in adipocyte differentiation. Front Med. 2013;7(2):223\u201330.","journal-title":"Front Med"},{"issue":"1","key":"3283_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/138920101601150105100851","volume":"16","author":"D Sekar","year":"2015","unstructured":"Sekar D, et al. Role of microRNA 21 in mesenchymal stem cell (MSC) differentiation: a powerful biomarker in MSCs derived cells. Curr Pharm Biotechnol. 2015;16(1):43\u20138.","journal-title":"Curr Pharm Biotechnol"},{"key":"3283_CR8","first-page":"11","volume":"14","author":"TG Ruksha","year":"2019","unstructured":"Ruksha TG. MicroRNAs\u2019 Control cancer cell Dormancy Cell Div. 2019;14:11.","journal-title":"MicroRNAs\u2019 Control cancer cell Dormancy Cell Div"},{"issue":"12","key":"3283_CR9","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","volume":"24","author":"G Reid","year":"2013","unstructured":"Reid G, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128\u201335.","journal-title":"Ann Oncol"},{"issue":"10","key":"3283_CR10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386\u201396.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3283_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mrgentox.2012.03.004","volume":"746","author":"G Zhang","year":"2012","unstructured":"Zhang G, et al. Cisplatin treatment leads to changes in nuclear protein and microRNA expression. Mutat Res. 2012;746(1):66\u201377.","journal-title":"Mutat Res"},{"key":"3283_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.omtn.2017.07.001","volume":"8","author":"HL Moody","year":"2017","unstructured":"Moody HL, Lind MJ, Maher SG. MicroRNA-31 regulates Chemosensitivity in Malignant Pleural Mesothelioma. Mol Ther Nucleic Acids. 2017;8:317\u201329.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"3283_CR13","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/cddis.2010.85","volume":"1","author":"N Bhatnagar","year":"2010","unstructured":"Bhatnagar N, et al. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010;1(12):e105.","journal-title":"Cell Death Dis"},{"issue":"2","key":"3283_CR14","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s13277-015-4081-z","volume":"37","author":"P Samuel","year":"2016","unstructured":"Samuel P, et al. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumour Biol. 2016;37(2):2565\u201373.","journal-title":"Tumour Biol"},{"issue":"5","key":"3283_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.rpor.2020.07.006","volume":"25","author":"T Kolenda","year":"2020","unstructured":"Kolenda T, et al. Good or not good: role of miR-18a in cancer biology. Rep Pract Oncol Radiother. 2020;25(5):808\u201319.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"6","key":"3283_CR16","first-page":"4161","volume":"19","author":"R Suzuki","year":"2020","unstructured":"Suzuki R, et al. Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin. Oncol Lett. 2020;19(6):4161\u20138.","journal-title":"Oncol Lett"},{"issue":"4","key":"3283_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jmoldx.2014.03.002","volume":"16","author":"M Andersen","year":"2014","unstructured":"Andersen M, et al. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma. J Mol Diagn. 2014;16(4):418\u201330.","journal-title":"J Mol Diagn"},{"issue":"6","key":"3283_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/cts.12323","volume":"8","author":"EI Papadopoulos","year":"2015","unstructured":"Papadopoulos EI, Scorilas A. Cisplatin and Paclitaxel alter the expression pattern of miR-143\/145 and miR-183\/96\/182 clusters in T24 bladder Cancer cells. Clin Transl Sci. 2015;8(6):668\u201375.","journal-title":"Clin Transl Sci"},{"issue":"20 Pt 1","key":"3283_CR19","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1158\/1078-0432.CCR-06-1056","volume":"12","author":"EP Spugnini","year":"2006","unstructured":"Spugnini EP, et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 2006;12(20 Pt 1):6133\u201343.","journal-title":"Clin Cancer Res"},{"key":"3283_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-9966-27-6","volume":"27","author":"EP Spugnini","year":"2008","unstructured":"Spugnini EP, et al. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. J Exp Clin Cancer Res. 2008;27:6.","journal-title":"J Exp Clin Cancer Res"},{"key":"3283_CR21","doi-asserted-by":"crossref","unstructured":"Cuciniello R, et al. Aglianico grape seed semi-polar extract exerts anticancer effects by modulating MDM2 expression and metabolic pathways. Cells. 2023;12(2):210.","DOI":"10.3390\/cells12020210"},{"issue":"9","key":"3283_CR22","doi-asserted-by":"publisher","first-page":"e7016","DOI":"10.1371\/journal.pone.0007016","volume":"4","author":"S Crispi","year":"2009","unstructured":"Crispi S, et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS ONE. 2009;4(9):e7016.","journal-title":"PLoS ONE"},{"issue":"4","key":"3283_CR23","doi-asserted-by":"publisher","first-page":"e18232","DOI":"10.1371\/journal.pone.0018232","volume":"6","author":"L Santarelli","year":"2011","unstructured":"Santarelli L, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS ONE. 2011;6(4):e18232.","journal-title":"PLoS ONE"},{"issue":"2","key":"3283_CR24","doi-asserted-by":"publisher","first-page":"e31630","DOI":"10.1371\/journal.pone.0031630","volume":"7","author":"F Cordero","year":"2012","unstructured":"Cordero F, et al. Optimizing a massive parallel sequencing workflow for quantitative miRNA expression analysis. PLoS ONE. 2012;7(2):e31630.","journal-title":"PLoS ONE"},{"key":"3283_CR25","doi-asserted-by":"crossref","unstructured":"Fattore L, et al. In vitro biophysical and biological characterization of lipid nanoparticles co-encapsulating oncosuppressors miR-199b-5p and mir-204-5p as potentiators of target therapy in metastatic melanoma. Int J Mol Sci. 21(6):1930.","DOI":"10.3390\/ijms21061930"},{"issue":"D1","key":"3283_CR26","doi-asserted-by":"publisher","first-page":"D127","DOI":"10.1093\/nar\/gkz757","volume":"48","author":"Y Chen","year":"2020","unstructured":"Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127\u201331.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3283_CR27","doi-asserted-by":"publisher","first-page":"D155","DOI":"10.1093\/nar\/gky1141","volume":"47","author":"A Kozomara","year":"2019","unstructured":"Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155\u201362.","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"3283_CR28","doi-asserted-by":"publisher","first-page":"11673","DOI":"10.1093\/nar\/gks901","volume":"40","author":"CE Vejnar","year":"2012","unstructured":"Vejnar CE, Zdobnov EM. MiRmap: comprehensive prediction of microRNA target repression strength. Nucleic Acids Res. 2012;40(22):11673\u201383.","journal-title":"Nucleic Acids Res"},{"key":"3283_CR29","doi-asserted-by":"crossref","unstructured":"Di Meo F, et al. Curcumin C3 complex\u00ae\/Bioperine\u00ae has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis. J Exp Clin Cancer Res. 2019;38(1):360.","DOI":"10.1186\/s13046-019-1368-8"},{"issue":"4","key":"3283_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/jclinpath-2020-206545","volume":"74","author":"EP Spugnini","year":"2021","unstructured":"Spugnini EP, et al. Filling the gap between histology and cytology: description of an innovative technology (Cytomatrix) to increase the diagnostic effectiveness of fine needle aspirates data. J Clin Pathol. 2021;74(4):269\u201370.","journal-title":"J Clin Pathol"},{"key":"3283_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.lungcan.2020.06.024","volume":"146","author":"L Cantini","year":"2020","unstructured":"Cantini L, et al. Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: a single center experience with systematic review and meta-analysis. Lung Cancer. 2020;146:318\u201326.","journal-title":"Lung Cancer"},{"issue":"8","key":"3283_CR32","doi-asserted-by":"publisher","first-page":"e23569","DOI":"10.1371\/journal.pone.0023569","volume":"6","author":"A Baldi","year":"2011","unstructured":"Baldi A, et al. Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS ONE. 2011;6(8):e23569.","journal-title":"PLoS ONE"},{"key":"3283_CR33","doi-asserted-by":"publisher","first-page":"154947","DOI":"10.1016\/j.prp.2023.154947","volume":"252","author":"A Salman","year":"2023","unstructured":"Salman A, et al. Deciphering signaling pathway interplay via miRNAs in malignant pleural mesothelioma. Pathol Res Pract. 2023;252:154947.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"3283_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","volume":"302","author":"B Zhang","year":"2007","unstructured":"Zhang B, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1\u201312.","journal-title":"Dev Biol"},{"issue":"3","key":"3283_CR35","doi-asserted-by":"publisher","first-page":"814","DOI":"10.20517\/cdr.2022.56","volume":"5","author":"M Cioce","year":"2022","unstructured":"Cioce M, et al. Butein-instigated mir-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of malignant pleural mesothelioma cells. Cancer Drug Resist. 2022;5(3):814\u201328.","journal-title":"Cancer Drug Resist"},{"key":"3283_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2020.08.027","volume":"494","author":"Y Wu","year":"2020","unstructured":"Wu Y, et al. The microRNA-424\/503 cluster: a master regulator of tumorigenesis and tumor progression with paradoxical roles in cancer. Cancer Lett. 2020;494:58\u201372.","journal-title":"Cancer Lett"},{"issue":"7","key":"3283_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1101\/gad.237404.114","volume":"28","author":"D Llobet-Navas","year":"2014","unstructured":"Llobet-Navas D, et al. The miR-424(322)\/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes Dev. 2014;28(7):765\u201382.","journal-title":"Genes Dev"},{"issue":"6","key":"3283_CR38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1101\/gad.292318.116","volume":"31","author":"R Rodriguez-Barrueco","year":"2017","unstructured":"Rodriguez-Barrueco R, et al. miR-424(322)\/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev. 2017;31(6):553\u201366.","journal-title":"Genes Dev"},{"issue":"13","key":"3283_CR39","doi-asserted-by":"publisher","first-page":"21719","DOI":"10.18632\/oncotarget.15559","volume":"8","author":"K Xu","year":"2017","unstructured":"Xu K, et al. Mir-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Oncotarget. 2017;8(13):21719\u201332.","journal-title":"Oncotarget"},{"issue":"21","key":"3283_CR40","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1021\/acs.accounts.1c00500","volume":"54","author":"M Qiu","year":"2021","unstructured":"Qiu M, et al. Developing biodegradable lipid nanoparticles for intracellular mRNA delivery and genome editing. Acc Chem Res. 2021;54(21):4001\u201311.","journal-title":"Acc Chem Res"},{"issue":"8","key":"3283_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5483\/BMBRep.2022.55.8.092","volume":"55","author":"SH Kim","year":"2022","unstructured":"Kim SH, Jung IR, Hwang SS. Emerging role of anti-proliferative protein BTG1 and BTG2. BMB Rep. 2022;55(8):380\u20138.","journal-title":"BMB Rep"},{"issue":"4","key":"3283_CR42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3892\/ol.2022.13494","volume":"24","author":"NQ Liu","year":"2022","unstructured":"Liu NQ, et al. Cyclin genes as potential novel prognostic biomarkers and therapeutic targets in breast cancer. Oncol Lett. 2022;24(4):374.","journal-title":"Oncol Lett"},{"issue":"1","key":"3283_CR43","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1186\/s12885-020-07278-2","volume":"20","author":"L Zhong","year":"2020","unstructured":"Zhong L, et al. Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers. BMC Cancer. 2020;20(1):766.","journal-title":"BMC Cancer"},{"issue":"2","key":"3283_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/jcp.20605","volume":"207","author":"J Zhong","year":"2006","unstructured":"Zhong J, et al. ERK1\/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol. 2006;207(2):540\u201352.","journal-title":"J Cell Physiol"},{"issue":"5","key":"3283_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/carcin\/bgac037","volume":"43","author":"D Peeney","year":"2022","unstructured":"Peeney D, et al. Unravelling the distinct biological functions and potential therapeutic applications of TIMP2 in cancer. Carcinogenesis. 2022;43(5):405\u201318.","journal-title":"Carcinogenesis"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03283-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:29:39Z","timestamp":1740176979000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03283-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3283"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03283-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For human samples used in this study, each subject gave a written informed consent in accordance with Italian law. Samples were processed under approval of the written consent statement by Ethical Committee of AOU of the Second University of Naples, Italy and of the University Hospital of Marche, Italy respectively. The animal study was performed according to the European Community Council Directive 2010\/63\/EU, approved by the local Ethical Committee for Animal Experiments of the ENEA, and authorized by the Italian Ministry of Health (PR 415\/2021 and extension EE25E.15.EXT.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}